MAVENCLAD is approved to treat two of them: RRMS and SPMS.
This is the most common type of MS. Over 85% of MS patients are initially diagnosed with RRMS.
RRMS is characterized by clearly defined attacks of new or worsening symptoms. These attacks—also called relapses or exacerbations—are followed by periods of partial or complete recovery, which are called remissions. During remissions, all symptoms may disappear, or some symptoms may continue and become permanent.
Most people who are diagnosed with RRMS will eventually transition to SPMS. This means that neurologic function and disability progression get worse over time. About 50% of people transition within a decade of their initial diagnosis, and about 90% transition within 25 years.
SPMS can be characterized at different points in time as either active or not active as well as with progression or without progression.
While there is no cure for MS, there are a variety of treatments available depending on the symptoms and difficulties a person may have. These may include steroids to treat relapses, specific treatments to manage symptoms, and disease-modifying therapies (DMTs) to help reduce the number of relapses.
DMTs are usually used to treat MS over a long period of time to help slow or reduce disability progression. They are not used to treat MS symptoms, but they may be able to help prolong the time between relapses as well as the severity.
There are 3 forms of DMTs used to treat MS: injections, infusions, and oral medications.
When it comes to MS treatment, there are a variety of options. What works for one person may not be right for someone else. So, if one MS treatment isn’t working, or the benefits don’t outweigh the risks, don’t be afraid to ask a healthcare provider about switching treatments.
MAVENCLAD is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, MAVENCLAD is generally used in people who have tried another MS medicine that they could not tolerate or that has not worked well enough.
MAVENCLAD is not recommended for use in people with clinically isolated syndrome (CIS).
It is not known if MAVENCLAD is safe and effective in children under 18 years of age, and is therefore not recommended.
MAVENCLAD may cause serious side effects, including:
Do not take MAVENCLAD if you:
Before you take MAVENCLAD, tell your healthcare provider about all of your medical conditions, including if you:
How should I take MAVENCLAD?
Your healthcare provider will continue to monitor your health during the 2 yearly treatment courses, and for at least another 2 years during which you do not need to take MAVENCLAD. It is not known if MAVENCLAD is safe and effective in people who restart MAVENCLAD treatment more than 2 years after completing 2 yearly treatment courses.
MAVENCLAD can cause serious side effects. If you have any of these symptoms listed below, call your healthcare provider right away:
The most common side effects of MAVENCLAD include: upper respiratory infection, headache, and low white blood cell counts.
These are not all the possible side effects of MAVENCLAD. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please see full Prescribing Information/Medication Guide, including serious side effects, for additional Important Safety Information.